MoonLake Immunotherapeutics MLTX Total Liabilities & Equity
Total Liabilities & Equity at other companies
Other financials
Where this comes from
Reported directly by MoonLake Immunotherapeutics in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The official record: MoonLake Immunotherapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about MoonLake Immunotherapeutics's total liabilities & equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is MoonLake Immunotherapeutics's total liabilities & equity?
- MoonLake Immunotherapeutics (MLTX) reported total liabilities & equity of $400.37M in Q1 2026.
- How has MoonLake Immunotherapeutics's total liabilities & equity changed year-over-year?
- MoonLake Immunotherapeutics's total liabilities & equity decreased by 21.7% year-over-year, from $511.26M to $400.37M.
- What is the long-term trend for MoonLake Immunotherapeutics's total liabilities & equity?
- Over 5 years (2020 to 2025), MoonLake Immunotherapeutics's total liabilities & equity has grown at a 29.5% compound annual growth rate (CAGR), from $116.63M to $424.43M.
- What does total liabilities & equity mean?
- Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.